Welcome to our dedicated page for CLBS news (Ticker: CLBS), a resource for investors and traders seeking the latest updates and insights on CLBS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CLBS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CLBS's position in the market.
Caladrius Biosciences (Nasdaq: CLBS) presented full results from the ESCaPE-CMD trial at the SCAI 2020 conference, demonstrating significant improvements in coronary flow reserve (CFR) and patient symptoms for those with coronary microvascular dysfunction (CMD) after a single administration of its autologous CD34+ cell therapy, CLBS16. The study showed a highly statistically significant increase in CFR (p=0.0045) at six months, indicating the potential for reversing CMD, particularly in women. The company plans to initiate a Phase 2b study for CLBS16 in fall 2020.
Summary not available.
Summary not available.